Krilogy Financial LLC Raises Position in Thermo Fisher Scientific Inc. $TMO

Krilogy Financial LLC grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 537.7% during the first quarter, according to its most recent filing with the SEC. The firm owned 7,824 shares of the medical research company’s stock after acquiring an additional 6,597 shares during the period. Krilogy Financial LLC’s holdings in Thermo Fisher Scientific were worth $4,037,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Assetmark Inc. boosted its position in shares of Thermo Fisher Scientific by 22.9% in the 4th quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock worth $21,819,000 after purchasing an additional 7,023 shares in the last quarter. Mackenzie Financial Corp increased its position in Thermo Fisher Scientific by 29.4% during the 3rd quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock valued at $134,130,000 after buying an additional 62,790 shares in the last quarter. North Dakota State Investment Board purchased a new position in Thermo Fisher Scientific during the fourth quarter valued at $7,505,000. Fisher Asset Management LLC boosted its holdings in Thermo Fisher Scientific by 1.2% in the third quarter. Fisher Asset Management LLC now owns 2,721,101 shares of the medical research company’s stock worth $1,319,789,000 after acquiring an additional 31,298 shares in the last quarter. Finally, Quadrant Capital Group LLC grew its stake in shares of Thermo Fisher Scientific by 30.9% in the third quarter. Quadrant Capital Group LLC now owns 14,277 shares of the medical research company’s stock worth $6,924,000 after acquiring an additional 3,369 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Royal Bank Of Canada set a $490.00 price target on Thermo Fisher Scientific and gave the stock a “sector perform” rating in a research report on Thursday, May 14th. Barclays reduced their price objective on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research note on Tuesday, April 14th. Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Piper Sandler assumed coverage on shares of Thermo Fisher Scientific in a report on Thursday, June 11th. They set a “neutral” rating and a $510.00 price target on the stock. Finally, Morgan Stanley restated an “overweight” rating and issued a $620.00 price objective on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $608.95.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $469.27 on Wednesday. Thermo Fisher Scientific Inc. has a one year low of $398.08 and a one year high of $643.99. The stock has a 50-day moving average of $475.31 and a 200 day moving average of $521.28. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The company has a market capitalization of $174.39 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 2.05 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same quarter in the prior year, the business earned $5.15 EPS. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be issued a $0.47 dividend. The ex-dividend date is Monday, June 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.34%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.